Join SMi for their 16th annual conference on Generics and Patent Strategies to be held in central London on 13th-14th May 2013. This event never fails to disappoint and will address the hottest topics and key challenges faced within the Generics industry today. Presentations and panel discussions hosted by some of the key opinion leaders within the field of generics will provide delegates with the opportunity to address the challenges faced both today and tomorrow. This year’s event tackles some of the regulatory challenges experienced when entering new markets. It will explore how to overcome some of the IP issues faced when challenging patents and takes a detailed look at the pricing pressures surrounding an already saturated marketplace.
It is undoubtedly a highly competitive industry and with some of the large innovator companies searching for a piece of the Generics pie, SMi’s 16th annual conference will provide the perfect opportunity to share, discuss and develop new strategies in order to overcome some of the issues faced within a highly competitive marketplace. This year’s agenda provides a truly comprehensive overview of the generics landscape and facilitates the formation of new partnerships and networking opportunities to better position our attendees moving forward.
This seasoned event has provided delegates year on year the perfect opportunity to discuss and develop ideas with industry leaders and provide a platform for developing new strategies moving forward. Testimonials from our highly successful event in 2012:
"Getting better every year” – Harvest Moon Pharmacueticals
"Overall, great meeting with expert speakers” – Sandoz
“Outstanding “- IMS health
• Overcome the challenges of API synthesis and conforming to new EU Bioequivalence guidelines
• Address the latest changes in regulatory affairs in key global markets
• Navigate around, and challenging IP’s with a topic focussed on the outcome of AstraZeneca’s filing for a breach of patent surrounding their gastro-protective compound Omeprazole.
• Consider the Impact of Asian markets on the European generics industry.
• Evaluate and develop strategies around Ever-greening practices employed by innovator companies to stave off Generic Competition.
|
Business Development Directors
Brand Manager
Chief Medical Officer
Clinical Regulatory Strategy Manager
Commercial Director
Head Global Licensing
Head of Pharmacology
Medical Affairs Director
Principal Scientist
VP Chemistry
VP, Research
Legal Council
|
Associate Clinicians
Chief Executive Officer
Chief Scientific Officer
Clinical Pharmacologist
Director of Medical Affairs
Head of Clinical Science
Managing Director
Medical Director
Vice President
VP, Clinical
Head of Regulatory affairs
Consultants
|
Bt 30; Daher CIS; E D P Valor S A; Great Lakes Regional Office; INDIAN HERBS RESEARCH & SUPPLY CO LTD; INDIAN HERBS SPECIALITIES; IXL Pharma Ltd; Mississippi TSA Aviation Operations; Petromax/former Moscomet LLC; R M Vredenburg & Co; SIMPEX PHARMA PVT LTD; SMITH & KENNER PHARMACEUTICALS (P) LTD; Subcommittee on Surface Transportation and Merchant Marine Infrastructure, Safety and Security; University Of Illinois; Vodafone Limited; Warrington Borough Council;